To develop and externally validate a nomogram that predicts risk of side-specific extraprostatic extension (EPE) at time of surgery, using commonly available preoperative markers.
Introduction
Extraprostatic extension (EPE) is an adverse prognostic factor in men with prostate cancer [1] . Excellent disease control with radical prostatectomy (RP) has been reported when prostate cancer is organ-confined [2, 3] . Conversely, EPE at time of surgery has been shown to be associated with increased risk of disease progression and poor prognosis overall, especially among men with positive surgical margins [4] .
Because of the proximity of the neurovascular bundle to the posterolateral surfaces of the prostate gland [5] , men with higher risk of EPE at the time of surgery are often managed with non-nerve-sparing RP, with the goal of achieving a negative surgical margin; however, this is associated with significantly worse post-surgical outcomes, particularly in terms of erectile function recovery and possibly urinary continence [6, 7] .
Surgical decision-making at RP is crucial to maximizing biochemical disease-free survival as well as quality of life [6] [7] [8] . Given that at least 20% of men currently undergoing RP for presumed localized disease are noted to have EPE [4] , the accurate prediction of preoperative EPE risk is of clinical importance to help surgeons better select patients for a nervesparing vs non-nerve sparing approach. Although previous attempts have been made to predict risk of EPE using preoperative markers [1, [9] [10] [11] [12] [13] [14] , a model with improved predictive accuracy and generalizability/external validity is still needed. In the present study we used a number of preoperative markers to develop, and subsequently externally validate, a nomogram that predicts risk of side-specific EPE at time of surgery.
Materials and Methods

Patient Population
After obtaining institutional review board approval, patient cohorts from the University Health Network (UHN), Toronto, and the Ottawa Hospital Research Institute (OHRI) were used for nomogram development and external validation, respectively. The UHN cohort consisted of 753 men, accounting for 1506 evaluable sides (cases). This was obtained by conducting a retrospective chart review of 1310 men who underwent RP between January 2009 and October 2015. Men with biopsy reports lacking side-specific data and missing outcome data were excluded from the study (n = 485). Those with anterior predominant tumours were excluded because of their distant location from the neurovascular bundle (n = 72), as our aim was to investigate only those cases that influence the decision to perform nervesparing surgery.
The OHRI cohort consisted of 311 men, accounting for 622 evaluable sides (cases). This was obtained from a prospectively collected and maintained database of 537 men undergoing RP between April 1992 and August 2014. Similar exclusion criteria were applied to this cohort (n = 226 excluded).
Baseline Characteristics and Outcome
The primary endpoint under investigation was presence or absence of EPE in the surgical specimen, defined as any tumour extension beyond the confines of the prostate. Baseline characteristics considered were: age at RP; PSA level; DRE positivity; prostate volume as measured by TRUS; presence of hypoechoic nodule on TRUS; side-specific percentage of positive cores; side-specific highest core involvement; and side-specific Gleason score (GS), which was divided into quartiles: Gleason grade group 1 (no cancer, prostatic intraepithelial neoplasia and GS 6); Gleason grade group 2 (GS 3 + 4 = 7); Gleason grade group 3 (GS 4 + 3 = 7); and Gleason grade group 4 (GS 8, 9, 10). No restriction on biopsy template (number of cores) was applied. Patients undergoing site-directed biopsies were included and biopsy variables obtained from these additional cores were assessed as usual. Men with biopsy cores obtained from the midprostate were omitted, because of difficulty of core assignment to a specific side. For patients with multiple biopsy results available, we considered only the last biopsy report. All the men had last biopsy performed within 6 months of date of subsequent RP.
Statistical Analyses
The association between the predictors and EPE was tested using univariate and multivariate logistic regression models.
Nomogram predictive accuracy was determined using the area under the receiver-operating characteristic curve (AUC). The extent to which our predictive model under-or overestimates risk of EPE was evaluated graphically with a non-parametric, local regression smoothing technique. Statistical significance was determined by a two-sided P value of <0.05. Statistical analysis was performed using SPSS version 22.0 (IBM Corp., Armonk, NY, USA) and SAS version 9.4 (SAS Institute, Cary, NC, USA).
Results
Participant characteristics, according to cohort of origin, are shown in Table 1 Table 2 shows the association between measured clinical and pathological markers and risk of lobespecific EPE. In the UHN cohort, there were four lobes (1.78%) with no cancer documented at biopsy but with ipsilateral EPE at time of surgery. There were five (12.5%) similar cases in the OHRI cohort (Table 2) .
On univariate analyses, age, PSA, DRE positivity, presence of hypoechoic nodule, percentage of positive cores, highest core involvement and GS were all statistically significant predictors of ipsilateral EPE (all P < 0.01). Prostate volume was not predictive of EPE risk (P = 0.31; Table 3 ).
On multivariate analyses, only age, PSA, percentage of positive cores, highest core involvement and GS remained significant predictors (P < 0.01) of EPE. DRE (P = 0.10) and presence of hypoechoic nodule on TRUS (P = 0.49) were no longer predictive of EPE risk ( Table 3) .
The nomogram is shown in Fig. 1 . The model showed AUCs of 0.88 and 0.74 in the development cohort and the external validation cohort, respectively (Table 4 and Figs 2 and 3). The difference in nomogram-calculated EPE risk between the two sides of each patient's prostate was >20% in 53.2% and 57.6% of all patients in the UHN and OHRI cohorts, respectively ( Table 5 ).
The local regression non-parametric smoothing plot is shown in Fig. 4 . Our nomogram underestimates the risk of EPE for predicted values between 0 and 40%, while overestimating this risk for predicted values between 40 and 100%.
Discussion
In the present study, we developed and externally validated a nomogram predicting the probability of side-specific EPE based on preoperative markers. Using age, PSA and sidespecific DRE, presence of hypoechoic nodule on TRUS, Gleason score, percentage of positive cores and maximum core involvement, the prediction AUC was 74% in an external validation cohort; that is, in a random sample of 100 discordant pairs, where one case has EPE and the other does not, our model correctly predicted cases of EPE 74 out of 100 times.
This nomogram adds to the urologist's preoperative surgical planning armamentarium, complementing studies such as those by Partin et al. [1, 9] , Briganti et al. [15] and Tewari et al. [16] . The multi-institutional nomogram developed by Partin et al. [1, 9] combined PSA levels, clinical stage and Gleason score to predict pathological stage for men with clinically localized prostate cancer. Although proven to be clinically useful, this model is limited by its modest predictive ability for organ-confined disease (67.3%) and isolated capsular penetration (59.6%), which is inferior to the AUC of 0.74 reported in the present study. Also, this algorithm does not specify side-specific risk of EPE, which can differ significantly between both sides of the same prostate (Table 5) , and subsequently influence surgical planning.
Consequently, Ohori et al. [10] developed an algorithm that predicts the presence and side of EPE using PSA levels and side-specific clinical stage, biopsy Gleason sum, percentage of positive cores, and percentage of cancer in cores, with an AUC of 0.81 (using an internal validation cohort). This model is limited by lack of external validation by the authors, which limits its generalizability to different patient populations, who could have different disease characteristics. This is highlighted by the differences in overall EPE rate, which was 17% in the study by Ohori et al., compared with 20% and 29% in the UHN and OHRI cohorts, respectively. Also, we believe it is important to consider patient age (which was absent from the study by Ohori et al.) as a significant predictor of EPE risk, as this has been identified in previous studies [17] and reaffirmed in our multivariate analysis (odds ratio 1.06; P < 0.01).
Nomograms, mathematical formulas or algorithms developed for predictive purposes, have been shown to perform better compared with expert physician judgment [18, 19] . When estimating the risk of a certain outcome, clinicians tend to rely on factors such as their personal knowledge and prior experiences. These estimates are likely to be influenced by subjective factors that lead to considerable inter-and intraobserver variability. Also, when faced with complex clinical situations, there is a natural tendency to adopt a heuristic approach that involves dichotomizing risk into high vs low groups. By contrast, by calculating exact numerical values, nomograms allow a more objective assessment of patient risk, which leads to better performance when compared with expert physician judgment. It is interesting to note that the physician participants in these comparative studies included expert urological oncologists, who would be expected to perform better than non-specialists. Thus, studies comparing nomograms vs non-specialists may potentially lead to even more convincing results in favour of these models.
The present study is strengthened by the performance of external validation, which confirms the generalizability of our prediction model to various populations and clinical scenarios. While there was an appreciable drop in AUC, from 0.88 in the UHN cohort to 0.74 in the OHRI cohort (Table 4) , such a drop is to be expected because of differences in the characteristics of the two populations likelihood of pathological EPE. By plotting local regression smoothing plots, we were able to identify when our model under/over-predicts risk of EPE, which is crucial to consider when calculating a patient's individual risk. Finally, by excluding men with anterior predominant tumours, who are routinely identified at our centre using preoperative MRI, we focused only on those cases that had the highest potential to influence our decision to perform nerve-sparing surgery, or not, as we usually perform nerve-sparing surgery in men with anterior predominant tumours.
The present study has several potential limitations. The significant proportion of men excluded (40% overall) suggests the potential for a selection bias; however, on further analysis, no significant differences were found between the included and excluded men in terms of baseline characteristics (P > 0.05), allowing us to conclude that these data were missing completely at random and did not threaten the validity of our results. The OHRI cohort used for validation included men who underwent RP as early as 1992. Such men underwent sextant biopsies as opposed to the current standard of 12-core biopsies. This difference in the validation cohort could theoretically have influenced the validation/AUC results; however, we theorize that this actually lowered our AUC, as we would expect our nomogram to have performed better in 
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© 2016 The Authors BJU International © 2016 BJU International a more contemporary cohort, similar to the one used to develop our model. Because of the low number of cases (EPE) in lobes with either no cancer or prostatic intraepithelial neoplasia (four and two, respectively), we grouped these lobes with those containing GS 6 disease for regression analysis purposes. Pathologically, we did not differentiate between cases of focal vs established EPE. These two groups have different prognoses, with previous studies reporting 5-year progression-free probabilities of 73% and 42% for the focal and established groups, respectively [20] . Although we accounted for side-specific data in our analysis, we were unable to assess the significance of tumour detection on apical vs basal sites on biopsy, as these data are not regularly reported in pathology reports at our institution. Finally, we did not evaluate the role of multiparametric MRI (mpMRI) as a preoperative predictor of EPE risk. mpMRI is gaining popularity as a preoperative staging tool [21] , and has been shown in some studies to significantly improve the accuracy of clinical nomograms for predicting EPE risk [22] ; however, a recent single-centre randomized trial showed no benefit of preoperative MRI in terms of minimizing positive surgical margins [23] . Given these findings, coupled with the fact that mpMRI has yet to be universally adopted as a preoperative staging tool and has limited availability in certain settings, we decided not to include it in the present model as our goal was to develop a nomogram that can be readily used in various practice settings. As mpMRI becomes a more commonly used preoperative staging tool and experience increases, future studies that incorporate this method into nomograms will be needed.
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